Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2020 09:54 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Inc.的Ampligen药物被FDA授予胰腺癌治疗孤儿药地位

佛罗里达州奥卡拉, Dec. 22, 2020 (GLOBE NEWSWIRE) -- 专注于免疫紊乱、病毒性疾病和多种癌症治疗药物研发的免疫制药公司AIM ImmunoTech Inc.（NYSE American: AIM）今天宣布，美国食品和药物管理局于2020年12月17日授予AIM公司的Ampligen（rintatolimod）胰腺癌治疗孤儿药认定地位。 ...
December 21, 2020 09:40 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer

OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders,...
December 21, 2020 06:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Inc.’s Drug Ampligen Awarded FDA’s Orphan Drug Designation Status for the Treatment of Pancreatic Cancer

OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders,...
November 25, 2020 08:45 ET | Source: AIM ImmunoTech Inc.

AIM宣布新冠肺炎治疗和预防工作里程碑，首例患者已在评估Ampligen作为癌症和新冠肺炎联合治疗方法组成部分的研究中接受用药

佛罗里达奥卡拉, Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（美国NYSE代码：AIM）今天宣布了开发新冠肺炎（由SARS-CoV-2病毒引起）新疗法/预防策略工作取得的进展。首先，AIM报告称，Roswell...
November 25, 2020 06:45 ET | Source: AIM ImmunoTech Inc.

AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the...
November 13, 2020 07:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Provides Third Quarter 2020 Business Update

OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders,...
November 02, 2020 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces PLOS ONE’s Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen’s Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

OCALA, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announced today the publication of statistically significant data detailing how its drug Ampligen could have a...
October 30, 2020 10:00 ET | Source: AIM ImmunoTech Inc.

BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year

TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. Gaines...
October 22, 2020 07:30 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate...
October 06, 2020 09:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen

OCALA, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) is pleased to announce that it has received Institutional Review Board (IRB) approval for the expansion of the...